Shi-MingTuMD
Oncology • Little Rock, ARProfessor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Dr. Tu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UAMS Medical Center
449 Jack Stephens Drive Winthrop P. Rockefeller Cancer Institute, Seventh Floor
Little Rock, AR 72205Phone+1 501-686-8530
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1990 - 1993
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1989 - 1990- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1987 - 1990
- University of Illinois College of Medicine at ChicagoInternship, Internal Medicine, 1987 - 1988
Washington University in St. Louis School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1992 - Present
FL State Medical License 2021 - Present
AR State Medical License 2021 - 2025
TX State Medical License 1993 - 2024
OK State Medical License 2020 - 2021- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Start of enrollment: 2002 Apr 01
- Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases Start of enrollment: 2002 Feb 01
- Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 67 citationsPhase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate CancerMary-Ellen Taplin, Meredith M. Regan, Yoo Joung Ko, Glenn J. Bubley, Stephen Duggan
Clinical Cancer Research. 2009-11-15 - 296 citationsPlatinum-Based Chemotherapy for Variant Castrate-Resistant Prostate CancerAna Aparicio, Andrea L. Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo
Clinical Cancer Research. 2013-07-01 - 273 citationsBone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.Shi Ming Tu, Randall E. Millikan, Bayabel Mengistu, Ebrahim S. Delpassand, Robert J. Amato
Lancet. 2001-02-03
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
